Clinical Trials Browser

Recruiting × INDUSTRY × belzutifan × Clear all

NCT07227402 2026-06-04

LITESPARK-033

Phase 3 Recruiting

Carcinoma, Carcinoma, Renal Cell

NCT07405164 2026-05-29

MK-6482-043

Phase 3 Recruiting

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT07489495 2026-05-29

LITESPARK-034

Phase 3 Recruiting

Carcinoma, Renal Cell

NCT04924075 2026-05-28

MK-6482-015

Phase 2 Recruiting

322 enrolled 1 FDA

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT07049926 2026-05-26

MK-3475-03C

Phase 1/2 Recruiting

Carcinoma, Renal Cell

NCT06428396 2026-05-18

LITESPARK-029

Phase 2 Recruiting

Breast Neoplasms

NCT02861573 2026-02-17

KEYNOTE-365

Phase 1/2 Recruiting

Metastatic Castration-Resistant Prostate Cancer

NCT06234605 2026-01-15

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

Phase 1 Recruiting

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis